203 related articles for article (PubMed ID: 34674340)
21. Streamlining genetic testing for women with ovarian cancer in a Northern California health care system.
Powell CB; Laurent C; Ciaravino G; Garcia C; Han L; Hoodfar E; Karlea A; Kobelka C; Lee J; Littell RD; Roh J; Vay A; Kushi LH
Gynecol Oncol; 2020 Oct; 159(1):221-228. PubMed ID: 32778409
[TBL] [Abstract][Full Text] [Related]
22. Impact of Implementing B-RST
Wernke K; Bellcross C; Gabram S; Ali N; Stanislaw C
Clin Breast Cancer; 2019 Aug; 19(4):e547-e555. PubMed ID: 31005475
[TBL] [Abstract][Full Text] [Related]
23. Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
Konstantinopoulos PA; Norquist B; Lacchetti C; Armstrong D; Grisham RN; Goodfellow PJ; Kohn EC; Levine DA; Liu JF; Lu KH; Sparacio D; Annunziata CM
J Clin Oncol; 2020 Apr; 38(11):1222-1245. PubMed ID: 31986064
[TBL] [Abstract][Full Text] [Related]
24. Disseminating universal genetic testing to a diverse, indigent patient population at a county hospital gynecologic oncology clinic.
Bednar EM; Sun CC; Camacho B; Terrell J; Rieber AG; Ramondetta LM; Freedman RS; Lu KH
Gynecol Oncol; 2019 Feb; 152(2):328-333. PubMed ID: 30528888
[TBL] [Abstract][Full Text] [Related]
25. Screening and prevention of hereditary gynecologic cancers.
Kehoe SM; Kauff ND
Semin Oncol; 2007 Oct; 34(5):406-10. PubMed ID: 17920895
[TBL] [Abstract][Full Text] [Related]
26. Disparities in gynecologic cancer genetics evaluation.
Hinchcliff EM; Bednar EM; Lu KH; Rauh-Hain JA
Gynecol Oncol; 2019 Apr; 153(1):184-191. PubMed ID: 30711300
[TBL] [Abstract][Full Text] [Related]
27. Reproductive and Hormonal Considerations in Women at Increased Risk for Hereditary Gynecologic Cancers: Society of Gynecologic Oncology and American Society for Reproductive Medicine Evidence-Based Review.
Chen LM; Blank SV; Burton E; Glass K; Penick E; Woodard T
Gynecol Oncol; 2019 Dec; 155(3):508-514. PubMed ID: 31606283
[TBL] [Abstract][Full Text] [Related]
28. Mainstreaming Genetic Testing for Epithelial Ovarian Cancer by Oncology Providers: A Survey of Current Practice.
Czekalski MA; Huziak RC; Durst AL; Taylor S; Mai PL
JCO Precis Oncol; 2022 Jan; 6():e2100409. PubMed ID: 35025618
[TBL] [Abstract][Full Text] [Related]
29. Characteristics of African American women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic.
Barrington DA; Champion ML; Boitano TKL; Walters-Haygood CL; Farmer MB; Alvarez RD; Estes JM; Leath CA
Gynecol Oncol; 2018 May; 149(2):337-340. PubMed ID: 29486991
[TBL] [Abstract][Full Text] [Related]
30. Gynecologic cancer prevention in Lynch syndrome/hereditary nonpolyposis colorectal cancer families.
Chen LM; Yang KY; Little SE; Cheung MK; Caughey AB
Obstet Gynecol; 2007 Jul; 110(1):18-25. PubMed ID: 17601891
[TBL] [Abstract][Full Text] [Related]
31. The genetic prediction of risk for gynecologic cancers.
Randall LM; Pothuri B
Gynecol Oncol; 2016 Apr; 141(1):10-6. PubMed ID: 27016223
[TBL] [Abstract][Full Text] [Related]
32. Hereditary breast-ovarian cancer: clinical findings and medical management.
Marshall M; Solomon S
Plast Surg Nurs; 2007; 27(3):124-7. PubMed ID: 17901820
[TBL] [Abstract][Full Text] [Related]
33. Key messages for communicating information about BRCA1 and BRCA2 to women with breast or ovarian cancer: Consensus across health professionals and service users.
Jacobs C; Pichert G; Harris J; Tucker K; Michie S
Psychooncology; 2017 Nov; 26(11):1818-1824. PubMed ID: 28101941
[TBL] [Abstract][Full Text] [Related]
34. "I think that a brief conversation from their provider can go a very long way": Patient and provider perspectives on barriers and facilitators of genetic testing after ovarian cancer.
Mallen AR; Conley CC; Fuzzell L; Ketcher D; Augusto BM; McIntyre M; Barton LV; Townsend MK; Fridley BL; Tworoger SS; Wenham RM; Vadaparampil ST
Support Care Cancer; 2021 May; 29(5):2663-2677. PubMed ID: 32975643
[TBL] [Abstract][Full Text] [Related]
35. Attitude towards hereditary cancer risk management among women with cancer in Taiwan.
Fang SY; Hsieh LL; Hung CF; Hung FH; Peng HP; Yang AS; Wang YA
Support Care Cancer; 2022 Apr; 30(4):3625-3632. PubMed ID: 35028717
[TBL] [Abstract][Full Text] [Related]
36. Implementation of a quality improvement project for universal genetic testing in women with ovarian cancer.
Uyar D; Neary J; Monroe A; Nugent M; Simpson P; Geurts JL
Gynecol Oncol; 2018 Jun; 149(3):565-569. PubMed ID: 29653687
[TBL] [Abstract][Full Text] [Related]
37. [Hereditary breast and ovarian cancer - indications for genetic testing, counseling and options for mutation carriers].
Bürki N
Ther Umsch; 2010 Jul; 67(7):359-66. PubMed ID: 20577964
[TBL] [Abstract][Full Text] [Related]
38. Frequency of actionable germline pathogenic variants identified through tumor next-generation sequencing in a gynecologic cancer cohort.
Karpel H; Manderski E; Pothuri B
Int J Gynecol Cancer; 2023 Jul; 33(7):1044-1050. PubMed ID: 36889816
[TBL] [Abstract][Full Text] [Related]
39. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.
Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D
Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443
[TBL] [Abstract][Full Text] [Related]
40. MAGENTA (Making Genetic testing accessible): a prospective randomized controlled trial comparing online genetic education and telephone genetic counseling for hereditary cancer genetic testing.
Rayes N; Bowen DJ; Coffin T; Nebgen D; Peterson C; Munsell MF; Gavin K; Lechner R; Crase J; Polinsky D; Romero I; Blank SV; Levine DA; Norquist BM; Swisher EM; Lu KH
BMC Cancer; 2019 Jul; 19(1):648. PubMed ID: 31266460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
